Health and Wellness Informatics News

Apollo Hospitals develops an AI heart disease risk prediction tool

This tool that Apollo Hospitals have developed provides a risk score that factors in the vital signs and lifestyle activities for a patient.

Apollo Hospitals is one of the biggest hospital chains in India. It has harnessed its ten years’ data for 4000000 patients to develop its AI heart disease risk prediction tool. It can predict the risk of various cardiovascular diseases.

Apollo has introduced its AI-powered Cardiovascular Disease Risk tool this year. It can provide a risk score based on the category of high, moderate, and minimal. It can take into account the lifestyle of the patients, such as diet, smoking preferences, physical activity, etc. Also, it will consider any kind of psychological stress or anxiety that can get reflected in as a respiratory rate or blood pressure reading.

This risk prediction tool is more accurate than Framingham Risk Score. They have validated this AI device in a long-term cohort health study of the Heart & Vascular Centre at Maastricht University Medical Center in the Netherlands. It also has validations from King George’s Medical University in Lucknow.

In 2016, India accounted for a fifth of total17.7 million deaths due to CVDs. Diseases like ischemic heart and stroke are very deadly. A Global Burden of Disease Study has also found that from 100000 Indians, 272 die from CVDs.

This latest tool derives actionable data insight from Microsoft Azure. It enables doctors to deliver very proactive, preemptive, and preventive care for risky individuals. It also empowers them to offer holistic advice to patients based on their lifestyle modification.

Studies are going on for the benefits of using artificial intelligence to predict heart risk. Omron and Kyoto University in Japan have joined to study the use of AI and health data to predict early signs of CVD. Researchers are also working on developing a tool to protect the risk of coronary heart di sources from heart CT scans.

AI-enabled device, VUNO has the potential to arrest the vital signs of cardiac arrest. This tool recently received regulatory approval for South Korea.